Background {#Sec1}
==========

BC and CRC are commonly diagnosed malignancies worldwide \[[@CR1], [@CR2]\]. According to cancer incidence data, 2014 by the National Cancer Control Programme, BC is the leading cancer among Sri Lankan women accounting for 25.2% of total cancers and CRC ranks fourth (6.9%) and fifth (7.3%) in males and females respectively \[[@CR3]\]. Early menarche, late menopause, being nulliparous, lack of breast feeding, use of oral contraceptives, and a family history of BC or other cancers are some of the major risk factors associated with BC \[[@CR4]\] while risk factors for CRCs include age, obesity, dietary factors, smoking, alcoholism and personal history of adenomatous polyps/inflammatory bowel diseases \[[@CR5]\].

*TP53*, a tumour suppressor gene is one of the key factors involved in tumour development, progression and prognosis. Somatic mutations in the *TP53* gene are reported in approximately 26.51% of BC and 43.32% of CRC cases \[[@CR1], [@CR6]\]. The *TP53* gene contains 11 exons and 10 introns and is located on the short arm of chromosome 17. The p53 protein is a phosphoprotein of 393 amino acid (55 kDa) which includes an amino-terminal acidic transcription activation domain (1--67), a proline rich region (67--98), a core DNA binding domain (98--303), a nuclear localization signal-containing region (303--323), an oligomerisation domain (323--363) and a C-terminal basic domain (363--393). It acts as a transcription factor for several target genes. The *CDKN1A* gene, major transcriptional target of p53, codes for the p21 cyclin-dependent kinase inhibitory protein which causes cell cycle arrest. *MDM2* is another important transcriptional target gene of p53, where the MDM2 protein controls the level of p53 by a negative auto--regulatory feedback loop in which MDM2 binds to and ubiquitinates p53, targeting it for proteasomal degradation \[[@CR7]\].

According to the COSMIC database, more than 50% of the *TP53* alterations are missense mutations. This is followed by non-sense mutations contributing to about 10% of total *TP53* alterations \[[@CR6]\]. The functional status of p53 has an impact on treatment efficacy \[[@CR8]\]. Thus, recognition of the functional status of p53 may benefit in the selection of treatment option and prognostication of treatment efficacy. Identification of hotspot regions of *TP53* variants is useful to prioritize screening of such regions prior to treatment in a resource limited setting such as Sri Lanka.

Most research on p53 including trends of incidence, genetic analysis and treatment response have been carried out in developed countries, while analysis of such trends and patterns in developing countries including Sri Lanka are limited. Since the types of *TP53* alterations and their frequencies have been suggested to be influenced by geographical factors and ethnicity, the current study intended to establish the mutation spectrum of *TP53* in Sri Lankan BC and CRC patients \[[@CR9], [@CR10]\]. This is the first report on *TP53* alterations in Sri Lankan patients with sporadic BC and CRC.

In addition, association of BCs with CRCs is controversial, as some studies have suggested that BC survivors are at a higher risk of developing CRC due to risk factors such as obesity and the level of exogenous and endogenous sex hormones \[[@CR11], [@CR12]\] while other studies have proposed that there are no such associations \[[@CR13]\]. In this study, we compared the mutation spectrum of *TP53* among BCs and CRCs to evaluate their genetic basis.

Furthermore, immunohistochemistry (IHC) was carried out to measure the protein expression of p53 and to correlate the immuno-detection of p53 with the mutational status of *TP53* gene. We also studied the expression of p53 downstream targets and compared those with the immune-detection of p53.

Methods {#Sec2}
=======

Recruitment of the participants for the study and processing of the samples {#Sec3}
---------------------------------------------------------------------------

Ethical clearance (EC/14/160) was granted by the Ethics Review Committee of the Faculty of Medicine, University of Colombo, Sri Lanka. A total of 92 participants were recruited, which includes 30 patients with BC, 21 patients with CRC and 41 healthy controls (30 females, 11 males) without any personal or family history of cancer.

Prior to the recruitment, the study was explained and written informed consent was obtained from the patients and healthy controls. Clinical and socio- demographic data of the participants were collected via medical reports and questionnaires respectively.

One part of the surgically excised tumor tissues was placed in 10% formalin to make Formalin Fixed Paraffin Embedded (FFPE) blocks, while the other part was placed immediately in Allprotect® Tissue Reagent (QIAGEN, cat no. 76405, Hilden, Germany) and stored at-20 °C until processed.

Genomic DNA extraction from the excised tumour piece of patients and from blood of healthy controls was carried out as in Manoharan et al., 2019 \[[@CR14]\]. PCR amplification of *TP53* exon and flanking genomic DNA sequences was performed. The nucleotide sequence of PCR primers used and reaction conditions have been previously reported \[[@CR14]\]. Wizard® SV Gel and PCR Clean-Up kit (Promega) was used to purify the PCR products. Direct sequencing was carried out for purified products using the BigDye® Terminator v3.1 kit (Thermo Fisher Scientific, Waltham, MA USA) and an Applied Biosystems™ 3500Dx Genetic Analyzer (ThermoFisher Scientific).

The sequencing results were analyzed through BioEdit® software by aligning with the Human NCBI *TP53* reference sequence (Genbank accession number - NC_000017) and confirmed further using Mutation Surveyor®V4.0.9 and Alamut® Visual 2.7.2 Documentation. Guidelines of the Human Genome Variation Society (HGVS) nomenclature (http:/[www.hgvs.org/mutnomen/](http://www.hgvs.org/mutnomen/)) were used to name the identified sequence variants.

Analysis of sequence variants {#Sec4}
-----------------------------

The following databases were used to check the identified sequence variants for previous reporting: Catalogue Of Somatic Mutations in Cancer (COSMIC) (<http://cancer.sanger.ac.uk/cosmic>); NCBI (<https://www.ncbi.nlm.nih.gov/>); IARC TP53 (<http://p53.iarc.fr/>); Ensembl (<https://asia.ensembl.org/index.html>); the p53 website (<https://p53.fr/tp53-database>).

Pathogenicity of exonic variants was analysed using comparative programs of missense prediction; Align GVGD (<http://agvgd.hci.utah.edu/agvgd_input.php>); SIFT (<http://sift.jcvi.org/www/SIFT_seq_submit2.html>); MutationTaster (<http://www.mutationtaster.org/>); PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>); Provean (<http://provean.jcvi.org/seq_submit.php>). Gene splicing was assessed using Human Splicing Finder V3.0 (<http://www.umd.be/HSF3/>) and splicing window of Alamut® Visual software. Data on structural and functional activity of the p53 available on IARC TP53 database such as transcriptional activity and Dominant Negative Effect was also considered for pathogenicity determination of the exonic variants identified \[[@CR15]\]. Classification of all variants was done according to the standards and guidelines of American College of Medical Genetics \[[@CR16]\].

Structure based activity prediction for the novel exonic variants was done using protein structure comparison software TM align (<https://zhanglab.ccmb.med.umich.edu/TM-align/>). The X-ray diffraction structure of wild type p53 protein complexed with DNA (PDB ID -- 1TUP) was used to identify the structural position of variant sequences. The structure of the protein with novel variants was built using SWISS-MODEL (<https://swissmodel.expasy.org/>).

Immuno expression of p53, p21 and MDM2 {#Sec5}
--------------------------------------

IHC characterization was performed on representative FFPE tumour sections of thirteen BC and fourteen CRC cases randomly selected, to evaluate the immuno expression of p53, p21, and MDM2. The commercially available primary antibodies used were mouse monoclonal Anti-Human p53 clone DO-7 (Agilent DaKo, Santa Clara, USA), Rabbit monoclonal p21 Waf1/Cip1 2947S (Cell signalling technology, Danvers, MA, USA) and mouse monoclonal Anti-MDM2 OP46 (MerkMillipore, Massachusetts, USA) for detecting of p53, p21 and MDM2 respectively. Trials were performed to optimise the concentration, incubation time of the primary antibodies and antigen retrieval buffer (Citrate, pH = 6 and Tris, pH = 9). The best outcomes were used for the samples and the optimised conditions are tabulated in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The paraffin-embedded pellets of MDM2 inhibitor treated (5 μM Nutlin-3) MCF7 cells was used as a positive control for p53 and p21 antibodies and paraffin-embedded pellets of MDM2 inhibitor treated (10 μM Nutlin-3) SJSA cells was used as a positive control for the MDM2 antibody. The general IHC conditions have been previously reported \[[@CR14]\]. AperioScanScope® CS System (Aperio Technologies, Bristol, UK) and Spectrum™ image management software were used to visualize the images of the IHC stained slides and the images were finally analysed as described in Manoharan et al., 2019 \[[@CR14]\].

Analysis of hotspot regions of KRAS, BRAF and PIK3CA {#Sec6}
----------------------------------------------------

PCR specific primers were designed to amplify the hotspot regions of *KRAS* (Codon 12, 13, 61 and 146), *BRAF* (codon 600) and *PIK3CA* (codon 1047). 17 CRC samples were subjected to PCR amplification followed by direct sequencing. The results obtained were analysed in the same manner as for *TP53.*

Statistical analysis {#Sec7}
--------------------

The Pearson's chi-squared test and Spearman's Rank Correlation tests were done to find the strength and the direction of the associations. A *p*-value \< 0.05 was considered as statistically significant at 5% level.

Results {#Sec8}
=======

Baseline characteristics of the study participants {#Sec9}
--------------------------------------------------

Mean (±SD) age of the studied patient cohort was 59.24 (±10.16) years for BC and 60.29 (±11.45) for CRC, 48.9 (±13.91) for healthy female controls and 49.01 (±17.14) for healthy male controls. The baseline characteristics of the BC and CRC patients are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} respectively. The majority of both BC and CRC patient population represents the Sinhalese ethnicity and were over 40 years in age. Table 1Clinicopathological characteristics of breast cancer patients and healthy controlsCharacteristicsTotal Number of patientsNumber of patients with Wild type *TP53*Number of patients with mutated *TP53*Number of healthy controlsEthnicity Sinhalese2518724 Tamil1105 Muslims2200 Burgher2021Age at study entry  \< 40 years1109 40--60 years1411313  \> 61 years151058Body Mass Index Underweight2202 Ideal9729 Overweight5414 Pre obese106411 Obese4224Tumour type Invasive Ductal Carcinoma29209N/A Invasive Lobular Carcinoma110N/ABreast affected Left1174N/A Right17134N/A both211N/AMenstrual status Pre menopausal75219 Post menopausal2316711Pregnancy history Nulliparous7439 1--3 children2116520  \> 3 children2111Breast Feeding history (Total) No breast feeding7439  \< = one year4318  \> one year1813513History of cancer Previous history633N/A Family history1183N/ACodon 72 polymorphism Arginine1210212 Proline7255 Arginine/ Proline119213 Table 2Baseline characteristics of colorectal cancer patients and healthy controlsCharacteristicsTotal Number of patientsNumber of patients with Wild type *TP53*Number of patients with mutated *TP53*Number of healthy controlsSex Male1412211 Female72510Ethnicity Sinhalese1912717 Tamil1104 Muslims1100Age at study entry 30--60 years97216  \> 60 years12755Body Mass index Under weight2201 Ideal Weight11558 Overweight6427 Pre obese2203 Obese0002Histological status of cancer Well differentiated adenocarcinoma321N/A Moderately differentiated adenocarcinoma1064N/A Poorly differentiated adenocarcinoma110N/A Unknown752N/ASmoking history Yes6603 No158718Alcohol consumption Yes9816 No126615Betel-quid chewing Yes10823 No116518Codon 72 polymorphism Arginine6516 Proline6335 Arginine/ Proline96310

Analysis of TP53 sequence variants {#Sec10}
----------------------------------

A total of 16 sequence variants were found in 30 BC patients and 15 sequence variants were found in 21 CRC patients. In healthy male and female controls 6 and 8 variants were found respectively. Table [3](#Tab3){ref-type="table"} illustrates the characteristics of each variant and detailed *in-silico* and functional analysis are given in Additional file [2](#MOESM2){ref-type="media"}: Table S2. Table 3Prediction of pathogenicity of identified variantsNoHGVS NomenclatureLocationMutation typeNo. of carriers in the study cohortNovel or reported and the code reported in databases for reported variants\*Pathogenicity prediction: *In-silico* or functionalConclusioncDNAProteinBC patients (*N* = 30)CRC patients (*N* = 21)Healthy controls -- Males (*N* = 11)Healthy controls - Females (*N* = 30)1c.848_849delGCp.Arg283Hisfs\*22E8F1000Novel*In-silico*Path2c.851_855delCAGAGp.Thr284Argfs\*20E8F1000Novel*In-silico*Path3c.431_433delAGCp.Gln144delE5IF0100Novel*In-silico*Path4c.637C \> Tp.Arg213\*E 6NS1100rs397516436*In-silico*Path5c.400 T \> Gp.Phe134ValE5M1000COSM43941BothPath6c.524G \> Ap.Arg175HisE 5M0100rs28934578, COSM10648BothPath7c.581 T \> Gp.Leu194ArgE6M0100rs1057519998, COSM44571BothPath8c.730G \> Tp.Gly244CysE7M1000COSM11524BothPath9c.733G \> Ap.Gly245SerE7M0200rs28934575, COSM6932BothPath10c.743G \> Ap.Arg248GlnE7M3000rs11540652/ COSM10662BothPath11c.840A \> Tp.Arg280SerE8M1000COSM44171BothPath12c.844C \> Tp.Arg282TrpE 8M0100rs28934574, COSM10704BothPath13c.626G \> Ap.Arg209LysE6M1000COSM45995BothLP14c.63C \> Tp.Asp21AspE 2S2001rs1800369--LB15c.459C \> Tp.Pro153ProE 5S0101rs72661116, COSM43964*In-silico*LB16c.903A \> Gp.Pro301ProE8S1000rs72661120/ COSM44165*In-silico*LB17c.-140G \> A--E 13'UTR1200novel--LB18c.97-29C \> A--I 3I1203rs17883323*In-silico*US19c.74 + 16G \> C--I 2I0100Novel--LB20c.74 + 38C \> G--I 2I2014624rs1642785--LB21c.96 + 41_96 + 56delACCTGGAGGGCTGGGG--I 3I2861127rs59758982--LB22c.97-52G \> A--I3I0001rs540683791--LB23c.782 + 72C \> T--I 7I11979rs12947788--LB24c.782 + 92 T \> G--I 7I11979rs12951053--LB25c.75-42G \> A--I 2I0010Novel--LB26c.782 + 79C \> T--I 7I0010Novel--LB27c.673-36G \> C--I 6I0100rs17880604*In-silico*B*Path* Pathogenic, *LP* Likely pathogenic, *US* variant with uncertain significance, *LB* Likely Benign, *B* Benign, *FS* Frameshift, *IF* In-frame, *M* Missense, *NS* Nonsense, *S* Silent, *I* Intron, *E* Exon, *3'UTR* 3′ Untranslated Region\*Details of *in-silico* and functional prediction are given in supplementary Table 2

Two novel frameshift variants were found in exon 8. The first of these, c.848_849delGC (Fig. [1](#Fig1){ref-type="fig"}), was observed in a 55 year old female BC patient with triple negative, poorly differentiated invasive ductal carcinoma, which results in an Arginine to Histidine substitution at the site of the deletion followed by other downstream amino acid changes and truncation of the protein at codon 303. The second frameshift variant, c.851_855delCAGAG (Fig. [1](#Fig1){ref-type="fig"}), was found in a 62 year old female BC patient with human epidermal growth factor receptor-2 (HER2) negative invasive ductal carcinoma with Ki67 index 32% and it result in a coding change from Threonine to Arginine at the site of deletion and other downstream amino acid encoding changes, plus a premature stop codon at position 302. Both the predicted truncated proteins are similar in length, with tetramerization and negative regulatory domains lost in both proteins. Fig. 1Novel frameshift deletions detected in exon 8. **a** Mutation Surveyor®V4.0.9 images indicating the heterozygous deletion point; R indicates the reference *TP53* sequence and S indicates the study sample *TP53* sequence. (i. - c.848_849delGC, ii - c.851_855delCAGAG). **b** Protein prediction using Mutalyzer 2.0.26. (i. - c.848_849delGC, ii - c.851_855delCAGAG). **c** Superimposed image of predicted mutated protein with wildtype p53 protein (PDB ID -- 1TUP) Red indicates the mutated protein, Blue indicates the wildtype protein (i. - c.848_849delGC, ii - c.851_855delCAGAG)

A novel 3-base pair in-frame deletion was identified in exon 5. c.431_433delAGC (Fig. [2](#Fig2){ref-type="fig"}), resulting in the loss of the Glutamine amino acid residue at position 144 present in the β strand of the DNA binding domain and produces a 392 amino acid, shorter by one amino acid compared with the 393 amino acid full length protein. It was detected in a 66-year-old female CRC patient with moderately differentiated adenocarcinoma who had a previous history of cervix cancer. This patient also had a pathogenic *KRAS* codon 12 variant sequence (c.35G \> A; rs121913529). Fig. 2Novel in-frame deletion c.431_433delAGC detected in exon 5. **a** Mutation Surveyor®V4.0.9 images indicating the heterozygous deletion point; R indicates the reference *TP53* sequence and S indicates the study sample *TP53* sequence. **b** Protein prediction using Mutalyzer 2.0.26. **c** Sequence chain view of wild type p53 (PDB ID -- 1TUP) protein showing the position of loss of the amino acid

A reported nonsense variant, c.637C \> T in exon 6 was found in both BC and CRC patients, resulting in a change from Arginine to a stop codon at 213. This truncated protein lacks part of the DNA binding domain, the tetramerization domain and negative regulatory domain, which would make the p53 protein non-functional. The BC patient was 47 years old with estrogen receptor (ER)/ progesterone receptor (PR) positive, HER2 equivocal invasive ductal carcinoma. The CRC patient was a 58 year old female with moderately differentiated adenocarcinoma.

There were four reported pathogenic missense variants, c.400 T \> G, c.730G \> T, c.743G \> A, c.840A \> T in exons 5, 7 and 8 observed only in BC patients. Variants c.400 T \> G, c.730G \> T and c.840A \> T were observed in one patient each, while c.743G \> A present in a CpG site was observed in 3 patients and 2 of them had triple negative invasive ductal carcinoma.

There were four reported pathogenic missense variants, c.524G \> A, c.581 T \> G, c.733G \> A, c.844C \> T in exon 5, 6, 7 and 8 respectively observed only in patients with CRC. A c.524G \> A variant was observed in a 67 year old male patient with moderately differentiated adenocarcinoma. He also had the pathogenic *KRAS* codon 61 variant (c.183A \> T; rs17851045). A c.581 T \> G substitution was found in a 65 year old female with well differentiated adenocarcinoma. The missense variant c.733G \> A was found in a 62 year old male patient with moderately differentiated adenocarcinoma and in a 71 year old female with tubular adenocarcinoma. A c.844C \> T substitution was reported in a 66 year old female with moderately differentiated adenocarcinoma, who had a previous history of ovarian cancer. She also carried the pathogenic *KRAS* codon 12 variant (c.34G \> C; rs121913530).

A likely pathogenic variant c.626G \> A in exon 6 was observed in a 48 year old BC patient with ductal carcinoma. There were also 2 silent variants with uncertain significance, of which, c.63C \> T appeared in 2 BC patients and in 1 female healthy control and c.459C \> T appeared in 1 CRC patient and in a healthy control. Another silent variant c.903A \> G observed in exon 8 in 1 BC patient is categorized as likely benign.

The codon 72 variant (p.R72P) in exon 4 is a well known *TP53* polymorphism. In the present study, R/R, R/P and P/P genotype distribution was 12 (40%), 11 (36.67%), 7 (23.33%) respectively in BC patients and 12 (40%), 13 (43.33%) and 5 (16.66%) respectively in healthy controls. No significant difference was observed (*p* = 0.78) in the prevalence of different genotypes in either the BC patients or the healthy controls. The genotypic distribution of R/R, R/P and P/P was 6 (28.57%), 9 (42.86%), 6 (28.57%) respectively in CRC patients and 6 (28.57%), 10 (47.62%) and 5 (23.81%) respectively in healthy controls. Similarly, there was also no significant difference (*p* value = 0.93) observed in the prevalence of different genotypes between the CRC patients and healthy controls.

Immunohistochemistry {#Sec11}
--------------------

The results obtained from immunohistochemistry analysis of 13 BC and 14 CRC tissue samples for IHC, were categorized into three; widespread IHC positive tumour nuclear staining involving either the entire or a segment of a tissue section (Pattern-A), rare/ scattered positive cells (Pattern-B) and complete absence of IHC positive signal (Pattern-C) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Different pattern of nuclear immunohistochemical expression of p53, p21 and MDM2 in **a** breast cancer tissue (Sample 37) and **b** colorectal cancer tissue (Sample 70) (Magnification 20X). p53 shows pattern A, p21 shows pattern B (red arrows indicate the rare positive cells) and MDM2 shows pattern **c** staining

Status of TP53 gene and the p53 protein expression {#Sec12}
--------------------------------------------------

For BC patients, positive IHC staining was detected in 7/13 (53.85%) cases. Three of these tumour sections showed pattern A, while 4 showed Pattern-B. All 3 BC cases that showed Pattern-A had *TP53* missense variants while the 4 cases that showed Pattern-B had no detectable pathogenic variants of *TP53*. Among the 6 cases with immuno-negativity (Pattern-C), one had a silent variant and the remaining 5 patients had wild-type *TP53.*

For CRC patients, positive IHC staining was observed in 11/14 (78.57%) cases. Four of these tumours showed pattern A, while 7 showed pattern-B. Among the 4 CRC samples that showed pattern A, 3 had a *TP53* missense variant each, while the remaining case had no detectable pathogenic variants. All 7 cases that showed pattern-B had no detectable pathogenic *TP53* variants. Among the 3 cases with pattern-C, one had a non-sense variant, another one had a silent variant and the remaining patient showing immuno-negativity had wild-type *TP53*.

Comparison of p53 protein expression with the expression p21 and MDM2 {#Sec13}
---------------------------------------------------------------------

Among the 3 BC samples showing p53 IHC staining with pattern A; 1 showed pattern B staining and the remaining 2 showed pattern C for p21. From the 4 samples with pattern B of p53 expression, 3 showed pattern B, while 1 showed pattern C for p21. All 6 samples with pattern C IHC for p53 also showed pattern C for p21. However, expression of MDM2 for all samples showed pattern C IHC staining, regardless of the expression pattern of p53 or p21 protein (Table [4](#Tab4){ref-type="table"}--1). Table 4Correlation between p53, p21, MDM2 expression with *TP53* gene status in (1) breast cancer and (2) colorectal cancer.

Among 4 CRC samples with pattern A p53 IHC staining, 2 showed pattern B and the remaining 2 showed pattern C staining for p21. All 7 samples with pattern B p53 IHC staining showed pattern B staining for p21. Among 3 with pattern C p53 IHC staining, 2 showed pattern C staining for p21 and the remaining one showed pattern A for p21 IHC staining. In the case of MDM2, among the 4 samples with p53 IHC staining with pattern A, 1 showed pattern B and the remaining 3 showed pattern C. From the 7 samples with pattern B of p53 expression, 4 showed pattern B, while 3 showed pattern C for MDM2. All 3 samples with pattern C IHC for p53 also showed pattern C for MDM2 (Table [4](#Tab4){ref-type="table"}--2).

Discussion {#Sec14}
==========

This is a preliminary study focused on the mutation spectrum of the *TP53* gene and expression of p53 and downstream p53 transcriptional proteins for a series of Sri Lankan BC and CRC patients.

Invasive ductal and lobular BCs are the major malignancies of the breast and account for approximately 80 and 15% of cases respectively \[[@CR17]\]. In our study cohort, 96.5% were ductal carcinoma and only 3.5% were the lobular carcinoma. The frequency of pathogenic *TP53* variation in the BC patient cohort (31%) was closer to figures reported in the cBioportal and IARC TP53 databases (32 and 22.8% respectively). But the frequency of pathogenic TP53 variation in the colorectal cancer cohort (33.3%) was lower compared to what has been reported in the cBioportal (53.4%) and IARC TP53 database (43.3%) \[[@CR15], [@CR18], [@CR19]\].

The incidence of overweight and obesity is increasing significantly worldwide, and it is associated with obesity-related cancers, including postmenopausal BC and CRC \[[@CR20]\]. In our study cohort 63.3% of the BC patients and 38.1% of the CRC patients were either overweight, pre-obese or obese based on Asian criteria for BMI cut-off.

Variant analysis {#Sec15}
----------------

All the 13 variants altering proteins are found between exons 5 to 8 and 9 (69%) of them are missense variants. It is supported by the data provided in IARC TP53 database as approximately 95% of the pathogenic variants are found between exons 5 to 8 and 73% of the alterations are missense variants. According to cosmic database, 53.14 and 52.83% of the alterations found in breast and colorectal cancers respectively are missense variants \[[@CR6], [@CR15]\].

Among the pathogenic variants found, the frameshift variants; c.848_849delGC, c.851_855delCAGAG and the in-frame variant; c.431_433delAGC have not been previously reported. The c.637C \> T, nonsense variant has been commonly reported in colon, breast, oesophageous, skin, and stomach cancers. The somatic missense variants; c.400 T \> G, c.524G \> A, c.581 T \> G, c.730G \> T, c.733G \> A, c.743G \> A, c.840A \> T and c.844C \> T have been reported in various cancers previously. However, c.730G \> T and c.840A \> T found in our BC patient cohort have been not previously reported in any type of BCs. On the other hand, c.524G \> A, c.733G \> A and 844C \> T found in the CRC patient cohort have been previously reported with a high prevalence in CRC cases. The likely pathogenic variant, c.626G \> A, observed in our BC cohort also has been reported in various cancers but not in BC. The c.63C \> T silent variant is reported only in the IARC TP53 database and the details are not provided. The c.459C \> T variant has been observed previously in BC but not in CRC, whereas c.903A \> G has been reported only in oesophageal and central nervous system cancers \[[@CR6], [@CR15]\].

The exonic variants c.637C \> T, c.524G \> A, c.844C \> T, c.63C \> T, c.459C \> T and c.-140G \> A found in this study were also observed in head and neck cancer patients by us \[[@CR14]\]. Comparison of *TP53* variants found in BCs with those in CRCs in this study showed c.637C \> T and c.-140G \> A were the only two exonic variants found in common. Among the seven pathogenic *TP53* variants found in CRC patients in the present cohort, only two were present in males suggesting a higher prevalence of pathogenic *TP53* variation in females when compared to males in CRC, although larger number of patient samples would need to be analysed to confirm this.

The most important factors that control the regulation of normal breast cell growth are p53 and hormone receptors PR, ER and HER-2. In normal breast tissues, cell proliferation is promoted by oestrogen. Stimulation of oestrogen also increases the level of p53 by both increasing the transcription and stabilization of p53. The increased level of p53 counters enhanced cell proliferation, thus keeping the proliferation and cell death in balance. However, in the cells where the p53 and ER levels are deregulated, the equilibrium between the cell proliferation and cell death is disturbed which leads to the uncontrolled tumour growth. Similarly, even PR and HER2 have functional interactions with mutant p53 \[[@CR1], [@CR21], [@CR22]\]. Studies have reported that of the tumours with *TP53* mutations, 55% are ER and PR negative, and 57% to be HER2 negative \[[@CR23]\]. According to the Multi-Omics Breast Cancer Database, all 3 patients reported with a tumour somatic c.743G \> A variant had a triple negative hormone status where the BC patient lacks ER, PR expression as well as HER2 expression \[[@CR24]\]. In our study, 2 out of the 3 patients detected with a c.743G \> A variant were triple negative and the other patient's receptor status is unknown. In addition, a patient with a c.848_849delGC variant tumour also had triple negative BC diagnosed.

Analysis of *KRAS*, *BRAF* and *PI3KCA* genes helps in the prognosis as well as in the treatment of colorectal cancer \[[@CR25]\]. Out of seventeen CRC patients analysed for *KRAS*, *BRAF* and *PIK3CA*, none of them had *BRAF* or *PIK3CA* pathogenic hotspot variant sequences, but 4 had pathogenic variants in *KRAS*; three in codon 12 and one in codon 61. Out of these 4 patients, three had pathogenic *TP53* variants; one had a previous history of cervical cancer and another had a previous history of ovarian cancer.

There are controversial opinions on the association of cancer risk and prognosis with codon 72 polymorphism, as some studies suggests that codon 72 Arginine has a protective effect based on a greater apoptotic potential \[[@CR26]--[@CR28]\] while others failed to replicate these findings \[[@CR29], [@CR30]\]. In the present study neither allele of p.R72P was significantly associated with BC or CRC. Similarly in our previous studies no significant association was found between the codon 72 polymorphism and head and neck cancer \[[@CR14]\]. However, the number of patients in the current study is too small to draw definitive negative conclusions about any association with cancer risk and prognosis.

Immunohistochemical analysis {#Sec16}
----------------------------

Wild type p53 has a very short half -- life, as it is generally kept under tight auto-regulatory control by MDM2. But in the case of mutant p53, the p53-dependent MDM2 expression is lost and mutant forms of p53 are no longer recognised by MDM2. The breakdown of the MDM2 mediated negative feedback loop leads to the accumulation of mutant p53 \[[@CR31], [@CR32]\]. All 6 missense variants identified in the current study were associated with the accumulation of mutant p53 protein resulting in the Pattern-A IHC staining, whereas all the samples (*N* = 11) with Pattern-B IHC were *TP53* wild-type. Six other wild-type samples, two samples with silent mutations and one sample with a nonsense variant showed no positive immuno-reactivity. Similar results were observed in our previous study on head and neck cancer \[[@CR14]\]. *TP53* missense mutations are strongly associated with the strong immuno positivity of p53 protein in breast (*p*-value = 0.001417) and breast and colorectal cancer combined (p-value = 8.104e-06). Several previous studies which observed an association between *TP53* mutations and higher expression of p53 protein in various types of cancer \[[@CR33], [@CR34]\] also support our findings. A larger study done on 7878 variants representing 60 distinct tumour sites from the IARC TP53 Database concludes that missense mutations are IHC positive while nonsense mutations, frameshift mutations and deletions were immunonegative \[[@CR35]\].

A number of studies have examined the relationship between the expression pattern of p53 and p21 in various human tumours with conflicting results. Some studies showed that abnormal p53 (overexpression) was associated with low or complete absence of expression of p21 \[[@CR36]--[@CR38]\], while others showed no significant correlation between p21 expression and the abnormal accumulation of p53 \[[@CR39], [@CR40]\]. Lack of correlation of p53 and p21 may be either due activation of p21 via p53 independent pathways or due to some p53 mutants being still able to transcriptionally turn on the p21 protein \[[@CR37]\]. Another important transcriptional target of p53 is MDM2. However, there are limited number of studies focused on the association of expression between p53 and MDM2. According to those studies, higher expression of both p53 and MDM2 was observed in most of the pancreatic cancer and sarcoma cases examined \[[@CR41], [@CR42]\]. This overexpression of MDM2 may be due to p53-independent transcriptional activation even in the presence of abnormal p53. In addition, functional studies have reported another novel mechanism of MDM2 stabilization and accumulation. MDM2 in tumour cells may be stabilized by interaction with mutant p53 and thus lead to accumulation \[[@CR43]\]. We attempted to investigate the functional activity of p53 by analysing the expression of the downstream proteins of p53 namely, p21 and MDM2 in our study cohort. There is no significant correlation observed between *TP53* gene status and p21 protein staining in breast cancer (*p*-value = 0.9214) and in colorectal cancer (p-value = 0.6426). Similarly, no significant correlation was found between *TP53* gene status and MDM2 protein both in breast cancer (p-value = 0.0522) and colorectal cancer (p-value = 0.6914). According to Spearman's Rank Correlation, there are no significant correlations in the expression of p21 and MDM2 in relation to expression of p53. This non-consistent pattern in the expression of p21 and MDM2 in relation to expression of p53 and mutational status of *TP53* may be due to the p53 independent pathways of p21 and MDM2 activation and the limited sample size. Thus, analysis of p21 and MDM2 protein expression in combination with p53 protein expression had no added advantage in differentiating between normal and mutant p53 protein.

Conclusion {#Sec17}
==========

We examined all exons and splicing sites of the *TP53* gene in BC and CRC in a cohort of Sri Lankan patients and found a high occurrence of gene alterations including several novel variants. All p53 protein altering variants found were positioned between exons 5--8. Only the point missense variants were associated with strong immuno-positive staining for p53. *TP53* wild type samples were associated with either rare isolated positively staining cells on tumour sections or complete absence of positive signal. Both truncating and silent variants were associated with the absence of positive IHC staining for p53. However there was no significant correlation found between the expression of p21 and MDM2 with the expression of p53.
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**Additional file 1: Table S1.** Optimised concentration, incubation time of the primary antibodies and antigen retrieval buffer **Additional file 2: Table S2.** *In-silico* and functional prediction of identified variants

BC

:   Breast cancer

CRC

:   Colorectal cancer

ER

:   Estrogen Receptor

FFPE

:   Formalin Fixed Paraffin Embedded

HER2

:   Human Epidermal growth factor Receptor-2

IHC

:   Immunoistochemistry

PCR

:   Polymerase Chain Reaction

PR

:   Progesterone Receptors
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